Community Bank & Trust Waco Texas Makes New Investment in Stryker Co. (NYSE:SYK)

Community Bank & Trust Waco Texas purchased a new position in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 780 shares of the medical technology company’s stock, valued at approximately $234,000.

A number of other large investors also recently made changes to their positions in SYK. Farmers & Merchants Trust Co of Chambersburg PA lifted its stake in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 61 shares during the period. HBC Financial Services PLLC acquired a new stake in shares of Stryker during the 4th quarter worth $37,000. Bourgeon Capital Management LLC acquired a new stake in shares of Stryker during the 4th quarter worth $37,000. Operose Advisors LLC increased its holdings in shares of Stryker by 308.6% during the 3rd quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after buying an additional 108 shares during the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in shares of Stryker by 97.1% during the 4th quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock worth $41,000 after buying an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research analyst reports. Citigroup upped their price objective on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a report on Wednesday, January 31st. Royal Bank of Canada increased their price target on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Roth Mkm increased their price target on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, Truist Financial increased their price target on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $340.45.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares in the company, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock worth $72,845,768 over the last ninety days. Company insiders own 5.50% of the company’s stock.

Stryker Stock Up 1.9 %

NYSE:SYK traded up $6.26 during mid-day trading on Tuesday, reaching $333.94. The stock had a trading volume of 804,516 shares, compared to its average volume of 1,271,239. The company has a market capitalization of $127.05 billion, a price-to-earnings ratio of 40.46, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The stock’s 50 day simple moving average is $349.74 and its two-hundred day simple moving average is $313.59. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same period last year, the firm earned $3.00 earnings per share. The company’s revenue for the quarter was up 11.8% compared to the same quarter last year. Equities analysts anticipate that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.96%. Stryker’s payout ratio is currently 38.79%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.